{"id":30826,"date":"2019-05-25T18:58:39","date_gmt":"2019-05-25T16:58:39","guid":{"rendered":"https:\/\/www.aiom.it\/?p=30826"},"modified":"2019-06-05T09:27:43","modified_gmt":"2019-06-05T07:27:43","slug":"2019-precision-oncology","status":"publish","type":"post","link":"https:\/\/www.aiom.it\/en\/2019-precision-oncology\/","title":{"rendered":"2019 Precision Oncology"},"content":{"rendered":"<p><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/05\/20190524-25RM_eng.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-30888 size-medium alignright\" src=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/05\/20190524-25RM_eng-210x300.jpg\" alt=\"\" width=\"210\" height=\"300\" srcset=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/05\/20190524-25RM_eng-210x300.jpg 210w, https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/05\/20190524-25RM_eng.jpg 543w\" sizes=\"auto, (max-width: 210px) 100vw, 210px\" \/><\/a><\/p>\n<h4>Rome, 24-25 may 2019<\/h4>\n<p><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524-25RM_Prog_EN-1.pdf\">Download the programme (PDF)<\/a><\/p>\n<hr \/>\n<ul>\n<li><strong><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_01_Gori.pdf\">Welcome<\/a><\/strong><br \/>\nStefania Gori, AIOM National President<\/li>\n<\/ul>\n<h3>SESSION I<br \/>\nA CHANGING WORLD\u2026<\/h3>\n<ul>\n<li><strong>Response Predictive factors to immunotherapeutic drugs from PDL-1 to Tumor Mutational Burden<\/strong>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_11_Vigliar.pdf\">The pathologist<\/a><br \/>\nG. Troncone, E. Vigliar<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_12_Danesi.pdf\">The pharmacologist<\/a><br \/>\nR. Danesi<\/li>\n<\/ul>\n<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_13_Vaccaro.pdf\">The tumor microenvironment and new drugs<\/a><br \/>\nF. Cognetti, V. Vaccaro<\/li>\n<\/ul>\n<h3>SESSION II<br \/>\nUNANSWERED QUERIES<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_21_Tommasi.pdf\">\u201cDriver\u201d mutation and \u201cPassenger\u201d mutation: what is the clinical meaning?<\/a><br \/>\nS. Tommasi<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_22_LoRusso.pdf\">The new immune-related response criteria (iRECIST): are always adequate<\/a><br \/>\nG. Lo Russo<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_23_DeLuca.pdf\">The design and conduct of clinical trials in the era of precision oncology: what is changing?<\/a><br \/>\nE. De Luca, M. Di Maio<\/li>\n<\/ul>\n<h3>SESSION III<br \/>\nBRCA MUTATED OVARIAN CARCINOMA<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_31_Cortesi.pdf\">AIOM-SIGU-SIBIOP-SIAPEC-IAP 2019 recommendations<\/a><br \/>\nL. Cortesi<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_32_Capoluongo.pdf\">The use of new genomic technologies in BRCA mutated ovarian cancer patients: what information?<\/a><br \/>\nE. Capoluongo<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_33_Toffoli.pdf\">Germinal pharmacogenetics<\/a><br \/>\nG. Toffoli<\/li>\n<\/ul>\n<h3>SESSION IV<br \/>\nONCOGENE-ADDICTED NSCLC<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_41_DelRe.pdf\">The development of resistances: clinical impact and therapeutic strategies<\/a><br \/>\nM. Del Re<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_42_Russo.pdf\">Liquid biopsy recommendations AIOM -SIAPEC-IAP-SIF-SIBioC<\/a><br \/>\nA. Russo<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_43_Bria.pdf\">Criteria of response during therapies in TKI: clinical or molecular criteria?<\/a><br \/>\nE. Bria<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_44_Delmonte.pdf\">The new targets: ROS1, MEK, NTRK<\/a><br \/>\nA. Delmonte<\/li>\n<\/ul>\n<h3>SESSION V<br \/>\nCOLORECTAL CARCINOMA<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_51_Lonardi.pdf\">Definition, effect, clinical course, therapies<\/a><br \/>\nS. Lonardi<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_52_Morano.pdf\">New therapies and scientific evidence<\/a><br \/>\nF. Morano<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_53_Bordonaro.pdf\">Position of regulatory bodies: FDA, EMA, AIFA<\/a><br \/>\nR. Bordonaro<\/li>\n<\/ul>\n<h3>SESSION VI<br \/>\nMALIGNANT MELANOMA, CEREBRAL AND UROLOGICAL NEOPLASMS<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_61_ChiarionSileni.pdf\">2019: adjuvant treatment of malignant melanoma<\/a><br \/>\nV.Chiarion Sileni<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_62_Lombardi.pdf\">New targets in brain neoplasms<\/a><br \/>\nG. Lombardi<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190524RM_63_Procopio.pdf\">BRCA2 and prostate carcinoma<\/a><br \/>\nG. Procopio<\/li>\n<\/ul>\n<h3>SESSION VII<br \/>\nBREAST CANCER<\/h3>\n<ul>\n<li><strong>PI3KA mutations and ER mutations: what impact on the outcome of breast cancer patients?<\/strong>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_71_Minotti.pdf\">The pharmacologist<\/a><br \/>\nG. Minotti<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_72_Fabi.pdf\">The oncologist<\/a><br \/>\nA. Fabi<\/li>\n<\/ul>\n<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_73_Guarneri.pdf\">BRCA mutated metastatic breast cancer: What is the role of PARP-I?<\/a><br \/>\nV. Guarneri<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_74_Sini.pdf\">Immunotherapy in breast cancer: what evidence?<\/a><br \/>\nV. Sini<\/li>\n<\/ul>\n<h3>SESSION VIII<br \/>\nNEW FRONTIERS<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_81_Severi.pdf\">Radio receptor therapy<\/a><br \/>\nS. Severi<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_82_Neri.pdf\">Radiomics<\/a><br \/>\nE. Neri<\/li>\n<\/ul>\n<h3>SESSION IX<br \/>\nTHE AGNOSTIC-TISSUE PRECISION MEDICINE: AN EMERGING APPROACH<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_91_Marchetti.pdf\">Rational and therapeutic bases<\/a><br \/>\nP. Marchetti<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_92_Montemurro.pdf\">New targets: are they always clinically useful?<\/a><br \/>\nF. Montemurro<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_93_Marchetti.pdf\">Ongoing clinical studies<\/a><br \/>\nM. Biffoni, P. Marchetti<\/li>\n<li><a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_94_Nicolis.pdf\">Patients\u2019 requests<\/a><br \/>\nF. Nicolis<\/li>\n<li><strong>Reading:<\/strong><br \/>\n<a href=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/02\/20190525RM_95_Conte.pdf\">The importance of interdisciplinary working groups in the age of precision oncology. The Molecular Tumor Board (MTB): from clinical indications to regulatory contexts<\/a><br \/>\nP. Conte<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.fondazioneaiom.it\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-30502 size-aiom_thumbnail\" src=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2019\/05\/2019_link_homeEN_FondazioneAIOM-300x170-300x170.jpg\" alt=\"\" width=\"300\" height=\"170\" \/><\/a><\/p>\n<h3>PARALLEL SESSION<br \/>\nAIOM FOUNDATION MEETS PATIENTS AND CITIZENS<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.fondazioneaiom.it\/wp-content\/uploads\/2019\/05\/20190525RM_F1_Russo.pdf\">Molecular target therapies in oncology: what results?<\/a><br \/>\nA. Russo<\/li>\n<li><a href=\"https:\/\/www.fondazioneaiom.it\/wp-content\/uploads\/2019\/05\/20190525RM_F2_Fabi.pdf\">Immunotherapy in oncology: results and perspectives<\/a><br \/>\nA. Fabi<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Rome, 24-25 may 2019 Download the programme (PDF) Welcome Stefania Gori, AIOM National President SESSION I A CHANGING WORLD\u2026 Response Predictive factors to immunotherapeutic drugs from PDL-1 to Tumor Mutational Burden The pathologist G. Troncone, E. Vigliar The pharmacologist R. Danesi The tumor microenvironment and new drugs F. Cognetti, V. Vaccaro SESSION II UNANSWERED QUERIES [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":30855,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[259],"tags":[],"class_list":["post-30826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aiom-meetings-en"],"_links":{"self":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts\/30826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/comments?post=30826"}],"version-history":[{"count":7,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts\/30826\/revisions"}],"predecessor-version":[{"id":31019,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts\/30826\/revisions\/31019"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/media\/30855"}],"wp:attachment":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/media?parent=30826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/categories?post=30826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/tags?post=30826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}